FULC (Fulcrum Therapeutics) OCF Margin %: 0.00% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FULC Fulcrum Therapeutics Inc FULC
44 GF Score
Price $3.73
GF Value $32.03
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is Fulcrum Therapeutics OCF Margin %?

Fulcrum Therapeutics FULC +0.95% 44 OCF Margin % is 0.00% as of Jun. 2026. GuruFocus rates FULC with a GF Score™ of 44/100 and a GF Value™ of $32.03 (Possible Value Trap). The stock has 1 warning sign investors should review. Among 954 Biotechnology companies, Fulcrum Therapeutics ranks worse than 104821.7% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Fulcrum Therapeutics's Cash Flow from Operations for the three months ended in Jun. 2026 was $-16.04 Mil. Fulcrum Therapeutics's Revenue for the three months ended in Jun. 2026 was $0.00 Mil. Therefore, Fulcrum Therapeutics's OCF Margin % for the quarter that ended in Jun. 2026 was 0.00%.

As of today, Fulcrum Therapeutics's current OCF Yield % is -23.18%.

The historical rank and industry rank for Fulcrum Therapeutics's OCF Margin % or its related term are showing as below:


During the past 9 years, the highest OCF Margin % of Fulcrum Therapeutics was -2.77%. The lowest was -3242.96%. And the median was -608.13%.

FULC's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -65.67
* Ranked among companies with meaningful OCF Margin % only.

Fulcrum Therapeutics OCF Margin % Related Terms

Fulcrum Therapeutics OCF Margin % Historical Data

* Premium members only.

The historical data trend for Fulcrum Therapeutics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fulcrum Therapeutics OCF Margin % Chart

Fulcrum Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only -409.53 -1,530.27 -3,242.96 -2.77 0.00

Fulcrum Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FULC
44GF Score
Fulcrum Therapeutics Inc FULC
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fulcrum Therapeutics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Fulcrum Therapeutics's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-60.065/0
= %

Fulcrum Therapeutics's OCF Margin for the quarter that ended in Jun. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Jun. 2026 )/Revenue (Q: Jun. 2026 )
=-16.039/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Fulcrum Therapeutics (FULC) has a OCF Margin % of 0.00% as of Jun. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Fulcrum Therapeutics and its competitors. According to the industry distribution chart, Fulcrum Therapeutics ranks #999999 out of 954 companies in the Biotechnology industry.
Is Fulcrum Therapeutics' OCF Margin % too high?
Fulcrum Therapeutics' current OCF Margin % is 0.00%. Based on the distribution chart, Fulcrum Therapeutics ranks #999999 out of 954 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Fulcrum Therapeutics has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Fulcrum Therapeutics' OCF Margin % compare to AGEN and IRD?
According to the Biotechnology industry distribution chart, Fulcrum Therapeutics ranks #999999 out of 954 companies for OCF Margin %. This places Fulcrum Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Fulcrum Therapeutics and its competitors. Fulcrum Therapeutics's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fulcrum Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Fulcrum Therapeutics (FULC) is currently considered Possible Value Trap. The stock's GF Value™ is $32.03, compared to a current price of $3.73 — trading 88.4% below its estimated fair value. The current OCF Margin % is 0.00%. Fulcrum Therapeutics' overall GF Score™ is 44/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Fulcrum Therapeutics (FULC), the current OCF Margin % is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fulcrum Therapeutics (FULC) Overvalued in 2026?

Based on GuruFocus' analysis, Fulcrum Therapeutics stock appears to be undervalued. The current stock price of $3.73 is trading 88.4% below its estimated GF Value™ of $32.03. GuruFocus considers Fulcrum Therapeutics to be Possible Value Trap.

Key valuation signals for FULC:

  • OCF Margin %: 0.00%
  • GF Value™: $32.03 vs. price of $3.73 (88.4% below fair value)
  • GF Score™: 44/100 with 1 warning sign

No single metric tells the full story. See the FULC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fulcrum Therapeutics Business Description

Address 26 Landsdowne Street, Cambridge, MA, USA, 02139
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.
44GF Score

Get the complete analysis for FULC

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.73
Price
$32.03
GF Value